KLK OLEO has announced the issuance of several patents covering formulation for effective tocotrienol delivery. The patents have been granted in Australia, India, the US, Indonesia, New Zealand and Japan. The company has additional patents in China, Europe, Macao and Singapore, among other territories.
The patent protects the company’s self-emulsifying drug delivery formulation for the improved delivery of tocotrienols. KLK’s commissioned an open-label, randomised, 4-way cross-over clinical study to compare the bioavailability of its E3 Bio-Enhanced 20 with a market sample. The study, done with 28 healthy volunteers, found the formulation delivered 46% higher bioavailability compared with the market sample.
